The 30-kDa protein (P32) is a mycobacterial secreted antigen which is homologous in Mycobacterium bovis and M. tuberculosis. In vitro, P32 induced T-cell proliferation. M. tuberculosis-or P32-stimulated T-cell lines lysed macrophages pulsed with P32 or M. tuberculosis, respectively. We conclude that P32 stimulates cytotoxic T cells specifically.
Tuberculosis is an infectious disease which afflicts 60 million individuals and is responsible for 3 million cases of death annually. Tuberculosis is no longer a major concern in developing countries only; incidences have dramatically increased in industrialized countries as well, primarily as a result of the AIDS epidemic. The emergence of multidrug-resistant Mycobacterium tuberculosis strains has exacerbated the situation. Thus, satisfactory control of the disease will depend on development of an effective new-generation vaccine.
Although protective immunity against tuberculosis crucially depends on helper T lymphocytes which activate tuberculostatic functions in macrophages, evidence has been presented that cytolytic T lymphocytes (CTL) are also required for optimum protection (8) . The majority of antigens with potential relevance for future subunit vaccines against tuberculosis that have been identified thus far are of somatic origin, and only few secreted antigens have been identified. However, for none of them has a clear association with protection been formally proven.
Because M. tuberculosis is capable of replicating inside macrophages, somatic proteins should not be available for presentation to T cells early after infection. Rather, proteins secreted by metabolically active M. tuberculosis organisms within macrophages should represent the major source of T-cell antigens. The antigen 85 complex, comprising the 85A, 85B, and 85C proteins, represents a dominant group of secreted 30-kDa proteins from M. tuberculosis, M. bovis, and other mycobacteria, and the 30-kDa protein cognates of M. bovis (P32) and M. tuberculosis are highly homologous (1, 4-6, 12-14, 22) . Evidence has been presented that P32 is expressed during human tuberculosis and leprosy infection and after M. bovis BCG vaccination, suggesting that it is a major target antigen of cellular and humoral immunity (9-11, 23, 24) . We investigated whether P32 in vitro induces human CTL, which have been implicated in both resistance to and the pathogenesis of tuberculosis (8, 17 with autologous irradiated (3,000 R) accessory cells (4 x 105/ml) and stimulated with purified P32 (15 ,ug/ml), lysates of M. tuberculosis H37Ra (batch 3114-33-8; 15 p.g/ml; Difco, Detroit, Mich.), concanavalin A (5 ,ug/ml; Sigma, St. Louis, Mo.), or heat-killed Listeria monocytogenes (incubation at 65°C for 120 min) (106/ml) for 2 days (mitogenic responses) or 7 days (antigen-specific responses) (5). Proliferation was measured by [3H]thymidine (1 ,uCi/ml; Amersham International, Amersham, England) uptake during the last 12 h. T cells from all six donors tested responded to lysates of M. tuberculosis (median = 134,987 cpm), P32 (median = 23,406 cpm), and heat-killed L. monocytogenes (median = 54,790 cpm) (P < 0.05; Wilcoxon signed U test; Table 1 ). Nonspecific T-cell expansion caused by P32 was not detected after 2 days of culture (545 cpm). After 7 days of culture of PBMC with P32 or with M. tuberculosis, CD4 T-cell proportions were increased, as determined by fluorescence-activated cell sorting (data not shown). These results demonstrate that P32 specifically stimulates and expands T cells. Accordingly, others have shown that P32 induces lymphoproliferation and gamma interferon production in whole blood cell cultures from normal individuals (7) .
Next, we expanded T-cell lines by bulk culture of PBMC (106/ml) with lysates of M. tuberculosis (50 ,ug/ml) and two to three cycles of 7-day antigen restimulation together with (18) . It has been proposed that CTL are required for optimum protection (8) . Therefore, our finding that P32-specific CTL recognize infected macrophages indicates that P32 is secreted and introduced into the macrophage processing and presentation machinery during infection. Although our study is limited to a small number of BCG-vaccinated individuals and needs to be extended to tuberculosis patients, our finding that P32 stimulated CTL of various fine epitope specificities suggests that P32 may be an important component of future subunit vaccines against mycobacterial infection.
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